DEEP RESEARCH · BOOSTIMMUNE

Boostimmune Deep Dive: Hunting for First-in-Class at the Intersection of ADC and Tumor Microenvironment

Pairing Tanaguchi-grade scientific originality with the global ADC megatrend — a "dual-engine" biotech strategy

Published: 2025-11-09 · Private biotech deep research · Original Naver blog post

0. Bottom Line First (Investment Thesis)

• Engine 1 (Science) — BIO-101 (TCTP/MDSC): A first-in-class IO asset rooted directly in Taniguchi's Nature Immunology research. By neutralizing TCTP it blocks MDSC recruitment — a route to overcome CPI non-response.
• Engine 2 (Commercial) — BIO-104 (Wnt/ADC): Tackles the notoriously "undruggable" Wnt/β-catenin pathway via an ADC modality — the commercial vanguard into the market Big Pharma is most aggressively betting on.
• Macro: Pfizer–Seagen $43B and Merck–Daiichi Sankyo $22B deals confirm ADC's promotion to oncology's mainstream. 2026 ADC market: ~₩17T ($15.4B).
• Policy: Korea's 3rd Five-Year Pharma/Bio Plan + K-Bio Lab Hub are positive for early-stage R&D biotech. Boostimmune's BIO-101 has been selected for a KDDF national R&D program, partially de-risking burn.

Synthesis: BIO-101 supports the valuation floor with a scientific moat, while BIO-104 (ADC) opens dramatic upside via licensing-out (L/O) into the global M&A wave.

I. Company Overview — An R&D-Only Biotech Built for Licensing

Business Model — L/O-Centric R&D Specialist

The company describes itself as a biotech "developing first-in-class therapeutics by targeting innovative and differentiated biological pathways" (About Us). Its pipeline spans immuno-oncology (IO), antibody-drug conjugates (ADC), and immune-stimulating antibody conjugates (ISAC).

The business model is NRDO / Venture-backed R&D: prove out concepts in pre-clinical and early clinical stages, then license out to Big Pharma. The capital-efficient nature is visible in the strategic MOU with WuXi Biologics and WuXi XDC.

Three-Year Cash-Flow Profile (Qualitative)

• Operating CF: Zero revenue, structurally negative — but it's a planned burn, not failure. Series A funds are deployed into BIO-101 pre-clinical entry/material production and ADC early development.
• Investing CF: Modestly negative, smaller than OCF. The WuXi MOU avoids buying antibody/ADC manufacturing assets in-house → minimal CAPEX.
• Financing CF: The only inflow line, strongly positive over three years: ₩500M Seed (2021) → ₩2.0B Pre-A (2021/8) → ₩17.0B Series A (2022/6) → cumulative ~₩20B (incl. TIPS).

Interpretation: Financial health reduces to runway — how long Series A funds the R&D burn.

Direct Customer — Big Pharma BD / S&E

The buyer is not patients or hospitals — it is the BD and Search & Evaluation groups inside Merck, Pfizer, AbbVie and peers, the same teams driving multi-billion-dollar M&A. Boostimmune is their outsourced "R&D engine" for early, high-risk assets.

The Moat — Layered

II. History & Key People

• Early 2021 — Co-founded by Kwanghee Lee and Prof. Tadatsugu Taniguchi.
• Jun 2021 — ₩500M Seed from Smilegate Investment (TIPS operator #1 deal).
• Aug 2021 — ₩2.0B Pre-A.
• Jun 2022 — ₩17.0B (~$13.4M) Series A closed.
• 2023 — BIO-101 selected for KDDF program (estimated).
• 2024 — MOU with WuXi Biologics & WuXi XDC for antibody/ADC development (estimated).

Founders & Key Hires

III. Pipeline Deep-Dive

BIO-101 — MDSC-suppressing IO (First-in-class)

• Target/MoA: First-in-class neutralizing antibody against TCTP (Translationally Controlled Tumor Protein). Extracellular TCTP released by dying tumor cells binds TLR2 and recruits MDSC into the TME → BIO-101 binds eTCTP and shuts down MDSC infiltration/activity, re-activating T-cell-mediated anti-tumor immunity.
• Differentiation: Current CPI therapies fail in "cold tumors" dominated by MDSC. BIO-101 can turn the TME "hot" → strong combination logic with CPI. Blood TCTP may also serve as a predictive biomarker for patient selection.
• Status: Pre-clinical. KDDF program (candidate development for BIO-101) + Series A funding aimed at an FDA IND submission targeted for late 2023.

BIO-104 — Wnt/β-catenin ADC

• Target/MoA: Targets the "undruggable" Wnt/β-catenin pathway — an area where direct attack historically caused severe toxicity because the pathway also matters in healthy tissue (why it isn't used routinely).
• Differentiation: Instead, BIO-104 hits a membrane protein that is specifically expressed and rapidly internalized in Wnt-addicted cancer cells — preserving the therapeutic window. Strong efficacy and safety demonstrated in HCC and uterine PDX models (pipeline page).

BIO-103 — Topoisomerase-1 Payload ADC

Same payload family as Daiichi Sankyo's Enhertu — a validated approach. Showed efficacy in SCLC and HCC PDX models with single-dose administration.

IV. Investors & Cap Table — "Strategic Investor Coalition"

Funding History

• Early 2021 — Seed ₩500M (Smilegate Investment, TIPS #1)
• 2021/8 — Pre-A ₩2.0B
• 2022/6 — Series A ₩17.0B (~$13.4M)
• Cumulative ~₩20B (incl. TIPS)
• Prior investors: Mirae Asset Financial Group, AJU IB Investment, Company K Partners, Smilegate Investment
• New investors: SV Investment, Premier Partners, We Ventures, Timefolio Asset Management

Why These VCs Matter

Interpretation: Not a collection of pure FIs — it's a strategic coalition aligned around global expansion and a Nasdaq IPO. Expect to see them play a decisive bridging role at IPO and L/O time.

V. Competition — A Blue Ocean Inside a Red Ocean

TCTP/MDSC Market (BIO-101)

• Direct competitors: Per KDDF documentation, no commercial competitor is currently pursuing "TCTP-neutralizing" MDSC suppression → an uncontested first-in-class position.
• Indirect competitors (other MDSC mechanisms): VISTA (PharmAbcine 'PMC-309'), TKI/STAT3 (Sunitinib), CXCR1/2 'SX-682', etc.
• Competitive thesis: If TCTP-TLR2 truly is a master regulator of MDSC trafficking, BIO-101 should achieve more upstream blockade than alternatives.

Wnt/β-catenin Market (BIO-104)

• History: Forty years of attempts — still no clinically usable Wnt drug. A graveyard.
• Other approaches: PF-06647020 (PTK7), F7-ADC (FZD7), PROTAC, ASO, VHH antibodies.
• Differentiator: Where competitors hit "known" membrane proteins (FZD7, PTK7), Boostimmune attacks a self-discovered, Wnt-addicted novel membrane protein — a "Blue Ocean" target with potentially distinct response and safety profiles.

VI. Growth Strategy & Outlook

Last Eight Quarters — Key Event

The dominant event was the Series A close (₩17B, Jun 2022). The capital was earmarked for ① BIO-101 pre-clinical entry and clinical-trial material production, and ② ADC early development — a dual bet on "Series B valuation via BIO-101 IND" plus "ADC L/O optionality". The WuXi MOU ensures the cash flows into R&D itself rather than facilities.

Risks

• Scientific/pipeline risk: Every asset is either first-in-class or undruggable → enormous upside if it works, but pre-clinical failure odds are extreme. TCTP may not be central to MDSC suppression as hypothesized; the BIO-104 Wnt proxy target may not preserve the therapeutic window in human trials.
• Financial risk: With no revenue, any delay in L/O can push the company into capital impairment. Time pressure to reach Series B or L/O before runway runs out.

Potential Overhang — VC Exit

Official fact: No specific mezzanine (CB/EB) issuance is identified in the source materials.

Interpretation: The overhang risk lies not in bonds but in the Series A and earlier VC preferred stock (RCPS/CPS). These will convert into common stock at IPO; ~₩20B is a potentially sellable overhang once lock-ups expire. This is the standard growth arc for VC-backed biotech — the real risk is not the overhang itself but a scenario where the IPO valuation is too low relative to VC entry, triggering selling pressure. Globally-oriented investors like AJU IB and SV typically optimize for post-IPO performance and may stagger exits.